Arix Bioscience announces first VIPE investment

  • Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis
  • Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine Oxidase drug discovery platform
  • First Venture Investment in Public Equity (VIPE) led by Arix, taking core portfolio to 14 companies.

Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an 11 per cent interest in Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.

To continue reading the press release please click here

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...